Clinical trials: Psoriasis; Plaque
Psoriasis, Overweight or Obesity
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1…
- Trial name
- NCT06857942
- Testing
- Tirzepatide
- Where
- 39 sites in United States
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Psoriasis
Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
This study is to evaluate the efficacy and safety of M518101 in subjects with plaque psoriasis
- Trial name
- NCT01878461
- Testing
- Vehicle, M518101
- Where
- 34 sites in United States
- Volunteers
- 542 people
- Sponsor
- Maruho North America Inc.
Moderate-to-severe Plaque Psoriasis
Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06258668
- Testing
- Deucravacitinib
- Where
- 2 sites in South Korea
- Volunteers
- 505 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)
This is an open-label, multicenter, parallel-group comparison study of the efficacy, safety, and tolerability of infliximab therapy in adult patients suffering from chronic plaque psoriasis (psoriasis vulgaris).
- Trial name
- NCT00254982
- Testing
- Infliximab
- Volunteers
- 593 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis
This study is a randomized, active-controlled, double-blind, phase 3 study to compare the efficacy and safety of CT-P43 to Stelara in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT04673786
- Testing
- CT-P43, Stelara
- Where
- Estonia
- Volunteers
- 509 people
- Sponsor
- Celltrion
Psoriasis
1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat
Evaluation of efficacy and safety of Mapracorat 0.1% ointment and 4 comparator ointments in male and female subjects 18 to 65 years with stable plaque-type psoriasis treated once daily 6 days a week for a maximum of 4 weeks.
- Trial name
- NCT03399526
- Testing
- Mapracorat (ZK 245186, BAY 86-5319), Prednicarbate 0.25% ointment, Clobetasol 0.05% ointment
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Bayer
Chronic Plaque Psoriasis
Safety and Tolerability of Repeat Courses of IM Alefacept
The purpose of this study is to determine whether repeat courses of alefacept, administered intramuscularly, are safe when given to chronic plaque psoriasis patients who are receiving standard dermatology treatments.
- Trial name
- NCT00233662
- Testing
- Alefacept
- Where
- 46 sites in United States, Austria and 7 more
- Volunteers
- 400 people
- Sponsor
- Biogen
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).
- Trial name
- BE BRIGHT (NCT03598790)
- Testing
- Bimekizumab
- Where
- 189 sites in United States, Australia and 11 more
- Volunteers
- 1,353 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- CHAMPION (NCT00235820)
- Testing
- adalimumab, MTX
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- Abbott
Plaque Psoriasis.
ASIS for Enbrel in Plaque Psoriasis
AUTOMATIC SUBDERMAL INJECTOR SYSTEM (ASIS) Corporation has developed and patented the only automatic injection system for delivery of injectable products to the optimum spot, just outside of the fascia, which exists subdermally…
- Trial name
- ASISinPP (NCT02112097)
- Testing
- Gadolinium, Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- ASIS Corporation
Plaque-type Psoriasis
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)
This study is being conducted to evaluate the efficacy and safety/tolerability of SCH 900222/MK-3222 in a population of participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT01936688
- Testing
- MK-3222 200 mg, MK-3222 100 mg, Etanercept 50 mg
- Sponsor
- Sun Pharmaceutical Industries Limited
Plaque Psoriasis
A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to determine the safety and efficacy of 2 doses of ABT-874 versus placebo in the treatment of subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT00570986
- Testing
- ABT-874
- Where
- 116 sites in United States, Canada
- Volunteers
- 1,465 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Plaque Psoriasis
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
This study will assess the use of risankizumab in adult patients with moderate to severe chronic plaque psoriasis and compare risankizumab to other commonly used biologics.
- Trial name
- VALUE (NCT03982394)
- Where
- 302 sites in Argentina, Australia and 19 more
- Volunteers
- 2,759 people
- Sponsor
- AbbVie
Psoriasis Vulgaris
Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This Phase II clinical study is to test safety and efficacy of BT061 against psoriasis given as repeated doses.
- Trial name
- NCT01072383
- Testing
- BT061
- Where
- 13 sites in Czechia, Hungary
- Volunteers
- 49 people
- Sponsor
- Biotest
Psoriasis
HPP737 in Adult Patients With Plaque Psoriasis
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737.
- Trial name
- NCT07712731
- Testing
- HPP737, Apremilast
- Where
- 60 sites in China
- Volunteers
- 607 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Rheumatoid Arthritis, Psoriatic Arthritis
A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
The purpose of the study is to assess systemic certolizumab pegol (CZP) exposure, the formation of anti-CZP antibodies and safety of CZP across the course of pregnancy in study participants with chronic inflammatory diseases.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis
- Trial name
- CHERISH (NCT04163016)
- Testing
- Pharmacokinetics of certolizumab pegol
- Where
- 9 sites in United States, France and 4 more
- Volunteers
- 22 people
- Sponsor
- UCB Biopharma SRL
Pharmacokinetics, Safety Issues
A Clinical Study With Adalimumab Biosimilar
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs.
- Trial name
- NCT06291948
- Testing
- Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product]
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Plaque Psoriasis
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
- Trial name
- ICONIC-ASCEND (NCT06934226)
- Testing
- JNJ-77242113, Ustekinumab
- Where
- 160 sites in United States, Argentina and 11 more
- Volunteers
- 752 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis, Plaque Psoriasis
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)
This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 2 to 5 years old) with plaque psoriasis:
- Trial name
- NCT04746911
- Testing
- ARQ-151 cream 0.3%
- Where
- 18 sites in United States, Canada and 1 more
- Volunteers
- 10 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Plaque Psoriasis, Healthy Volunteer
A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and food effect of UA026 tablets.
- Trial name
- NCT07038720
- Testing
- UA026
- Where
- China
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Usynova Pharmaceuticals Ltd.